Tipsheet
What matters at India’s listed companies
Earnings · Diagnostics · Mid cap

Thyrocare's Q1 transcript confirms 24% revenue growth, 34% PAT rise

The transcript of Thyrocare's Q1 FY27 earnings call adds no surprises but reaffirms the company's guidance of mid-to-high teens revenue growth for the year.


Mkt cap₹8,232 cr
P/E50.37×
ROE27.91%
Debt / eq.0.00
Div yld2.51%
24% revenue growth Q1 FY27 year-on-year

What's new

  • Revenue grew 24% YoY in Q1 FY27, PAT up 34%.
  • Active franchisees stood at 11,700; specialty diagnostics launched.
  • Management guides for mid-to-high teens revenue growth in full FY27.

Why this matters

The transcript confirms the momentum in Thyrocare's franchise and partnership model. The guidance implies sustained double-digit expansion, though high P/E of 50.4 leaves little room for disappointment. The planned radiology divestment could sharpen focus on core diagnostics.

What we're watching

  • Execution on the mid-to-high teens guidance in upcoming quarters.
  • Progress on specialty diagnostics rollout and radiology divestment.
  • Impact of franchisee network expansion on margins.

The full read

Thyrocare's Q1 FY27 earnings call transcript adds no news to already-public results but fills in the texture: 24% revenue growth, 34% PAT increase, 11,700 active franchisees. The company is launching specialty diagnostics and planning a radiology divestment. Guidance is mid-to-high teens revenue growth for the full year, consistent with the trailing 19.7% growth. With zero debt and an ROE of 27.9%, the execution path is clear. The high P/E of 50.4 leaves little room for error, but the transcript offers no cause for concern. Routine and reassuring.

Questions answered

What was Thyrocare's revenue and profit growth in Q1 FY27?
Revenue grew 24% YoY and PAT increased 34% in Q1 FY27, as confirmed in the earnings call transcript.
What is the company's revenue growth guidance for FY27?
Management guided for mid-to-high teens revenue growth for the full fiscal year FY27.
How many active franchisees does Thyrocare have?
Active franchisees reached 11,700, reflecting the company's focus on the franchise and partnership business.
What are the key strategic initiatives discussed on the call?
Launch of specialty diagnostics and plans to divest the radiology business to sharpen focus.
Does the transcript contain any new material information not previously disclosed?
No, the transcript is backward-looking and confirms information already in the public domain from the earlier results announcement.
Mentioned: Rahul Guha · 11,700 active franchisees · mid-to-high teens revenue guidance
Primary source BSE · NSE · Tijori

An independent reading of the company's own disclosure — the primary filing above is the final word.

Company snapshot

Thyrocare Technologies Ltd.

Diagnostic Chains
₹9,287 cr
P/E 52.68×

Latest quarter · Jun 2026

Sales₹240 cr
Net profit₹51 cr
Op. margin+32.2%
EPS₹3.28

Strength & growth

Debt / equity0.00×
Current ratio3.39×
Sales CAGR+13.2%
EPS CAGR+11.6%